Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PDUFA funds sought for postmarketing reviews, Public Citizen's Wolfe testifies at Senate hearing.

Executive Summary

USER FEE FUNDING OF POSTMARKETING REVIEWS SOUGHT BY PUBLIC CITIZEN's Health Research Group to address the growing workload at FDA's Division of Drug Marketing, Advertising & Communications, according to the testimony of HRG Director Sidney Wolfe, MD, at an April 11 hearing of the Senate Labor & Human Resources Committee. Wolfe noted that the number of drug launch campaigns jumped from 118 in FY 1993 to over 300 in FY 1996. During that same interval, the number of notice of violation letters issued by DDMAC dropped from 247 to 137. Wolfe attributed the decline in NOV letters to a static staffing level at DDMAC.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS030076

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel